Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Idronoxil (Primary) ; PSMA 617 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LuPin; LuPIN-1
- 30 Sep 2019 Results from review of interim data of the study, presented in a Noxopharm media release.
- 26 Jun 2019 Interim results presented in a Noxopharm media release.
- 23 May 2019 Planned number of patients changed from 32 to 56, according to a Noxopharm media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History